QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ARWR

QT60Arrowhead Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
81.82
+0.78+0.96%
OverviewShort InterestFilings
ARWRQT60Arrowhead Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
81.82+0.96%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.14
Insider Own5.49%
Shs Outstand140.86M
Perf Week9.96%
Market Cap11.42BForward P/E-EPS next Y-3.90Insider Trans-0.11%Shs Float-Perf Month11.81%
Enterprise Value12.60BPEG0.00EPS next Q-1.17Inst Own-Short Float-Perf Quarter43.64%
Income-297932838.00P/S18.35EPS this Y-45.80%Inst Trans-Short Ratio-Perf Half Y26.54%
Sales622.01MP/B18.80EPS next Y-24.84%ROA-13.27%Short Interest-Perf YTD23.24%
Book/sh4.25P/C-EPS next 5Y-ROE-55.45%52W High84.55 -3.23%Perf Year427.87%
Cash/sh12.67P/FCF-EPS past 3/5Y-ROIC-10.98%52W Low14.30 472.17%Perf 3Y-
Dividend Est.-EV/EBITDA-93.70Sales past 3/5Y50.54% 56.61%Gross Margin100.00%Volatility3.27% 3.44%Perf 5Y-
Dividend TTM-EV/Sales20.26EPS Y/Y TTM57.00%Oper. Margin-35.67%ATR (14)4.06Perf 10Y-
Dividend Ex-Date-Quick Ratio6.23Sales Y/Y TTM15450.00%Profit Margin-48.38%RSI (14)62.40Recom2.20
Dividend Gr. 3/5Y-Current Ratio6.23EPS Q/Q-133.82%SMA207.99%Beta1.63Target Price84.00
Payout0.00%Debt/Eq2.24Sales Q/Q-86.37%SMA5010.36%Rel Volume2.20Prev Close81.04
Employees609LT Debt/Eq0.63EarningsAug 06SMA20040.79%Avg Volume1.76MPrice81.82
IPO DateDec 16, 1993Option/ShortYes / YesEPS/Sales Surpr.14.68% 0.00%Net Debt/EBITDA-8.81Volume3,863,359Change0.96%
Analyst Ratings
DateActionAnalystRatingTarget
May-13-26ReiteratedBernsteinMarket Perform$35 → $46
May-08-26ReiteratedChardan CapitalBuy$80 → $90
Apr-21-26UpgradeMorgan StanleyEqual Weight → Overweight$78 → $100
Feb-06-26ReiteratedMorgan StanleyEqual Weight$81 → $78
Jan-27-26ReiteratedRobert W. Baird$81
Jan-21-26ReiteratedH.C. Wainwright$85 → $100
Jan-13-26ReiteratedUBS$110
Jan-13-26ReiteratedPiper SandlerOverweight$100 → $110
Jan-07-26ReiteratedMorgan StanleyEqual Weight$48 → $81
Jan-07-26ReiteratedChardan CapitalBuy$80
Latest News
Jun-18-26
Jun-18-2611:30AM
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D WebinarsYahoo
Jun-17-26
Jun-17-2610:48AM
Leerink Partners Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $72Benzinga
Jun-10-26
Jun-10-2603:02PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue6228294
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A0019
Gross Profit622829-15
Selling, General and Administrative Excl. Other15412297
Research and Development687607489
Other Operating Expense220
Operating Income-22298-601
Interest Expense938932
Unusual Expense
———
Non-Operating Income (Expense)-63-43-21
Net Income Before Taxes-25352-612
Income Taxes2021-3
Consolidated Net Income-301-2-599
Net Income From Continuing Operations-27330-610
Net Income-301-2-599
EPS (Recurring)-2.14-0.01-5.00
EPS (Basic, Before Extraordinaries)-2.14-0.01-5.00
EPS (Diluted)-2.14-0.01-5.00
EBITDA-134165-562
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio18.685.57—
Gross Margin100.00100.00-375.00
Operating Margin-35.6911.82-15,025.00
Net Margin-48.39-0.24-14,975.00
Shares Outstanding142134120
Market Capitalization11,6184,622—
Operating Lease Expense
———
Insider Trading Volume
$91.38$82.37$73.36$64.35$55.34● Close Price0.00M6.64M13.29M19.93M26.58MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Lu HongboDirectorMay 12 '26Sale76.882,970228,33452,012May 14 12:00 AM
Hamilton James CChief Medical OfficerApr 23 '26Sale75.0010,000750,000226,958Apr 24 12:00 AM
Apel Daniel JosephChief Financial OfficerApr 22 '26Sale71.3513,095934,286162,905Apr 24 12:00 AM
Hamilton James CChief Medical OfficerMar 05 '26Sale64.1910,000641,900236,958Mar 09 12:00 AM
Hamilton James CChief Medical OfficerJan 05 '26Sale63.1140,1642,534,661171,958Jan 05 12:00 AM
O'Brien PatrickCOOJan 05 '26Sale63.1149,4933,123,349474,908Jan 05 12:00 AM
Anzalone Christopher RichardChief Executive OfficerJan 02 '26Sale66.1013,187871,7033,792,739Jan 05 12:00 AM
Anzalone Christopher RichardChief Executive OfficerDec 29 '25Option Exercise6.15103,452636,2303,857,652Dec 30 12:00 AM
Anzalone Christopher RichardChief Executive OfficerDec 29 '25Sale69.1351,7263,575,5753,805,926Dec 30 12:00 AM
Ferrari MauroDirectorDec 26 '25Sale70.007,530527,10069,053Dec 30 12:00 AM
Anzalone Christopher RichardChief Executive OfficerDec 22 '25Sale68.4412,586861,3403,805,926Dec 23 12:00 AM
Vakiener VictoriaDirectorDec 19 '25Sale67.6810,040679,49135,723Dec 23 12:00 AM
Waddill William D.DirectorDec 19 '25Sale67.658,367566,03956,563Dec 23 12:00 AM
Anzalone Christopher RichardChief Executive OfficerDec 19 '25Sale67.6613,445909,6823,818,512Dec 23 12:00 AM
OLUKOTUN ADEOYE YDirectorDec 19 '25Sale67.6610,000676,62333,600Dec 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR